Overview

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Status:
Active, not recruiting
Trial end date:
2022-03-07
Target enrollment:
Participant gender:
Summary
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca